CHF 14 million to fund hemotune’s clinical trials


Following the successful completion of preclinical development for their nano-based blood purification platform, hemotune closed a CHF 14 million Series B2 round. The funds will be used to move into clinical trials.

The HemoSystem, a breakthrough blood purification platform based on nanoengineered magnetic beads, stands out for its ability to effectively remove large biomolecules directly from patients' bloodstreams, offering a unique approach to implement precision medicine multi-target treatments which would not be possible through drugs. Hemotune initially focussed on Sepsis. Given the serious impact of sepsis, which leads to around 11 million deaths annually and is a major economic burden, the potential benefits of this innovative technology are significant for patients and healthcare systems alike. In addition to treating sepsis-related immune suppression, hemotune also plans to explore other potential uses for the platform in the future.

The investment was led by Belmondo with continued support of existing investors including VP Venture Partners, HEMEX, OCCIDENT, Zürcher Kantonalbank, and joined by EFI. Lukas Langenegger, CEO and co-founder of hemotune AG, states: "As we navigate through a challenging fundraising climate, the success of our Series B2 funding round underscores not only the potential of our innovative blood purification platform but also the confidence our backers have in our team and vision to revolutionize medical treatment."

Dr. Darius Madjdpour, founder at Belmondo comments: "The team of hemotune has managed to develop one of the most promising platform technologies I have seen in medicine. The possibilities to tackle various diseases and enabling therapies through HemoSystem has convinced us to take the lead in this funding round."

Cédric Barra, Senior Investment Manager at OCCIDENT adds: “This Series B2 funding will now pave the way for clinical trials. The company has done an excellent job over the last few years to get to this point and we hope that hemotune can make the therapy available to patients soon.”

Pascal Winnen, CEO of HEMEX, asserts: "With our established expertise as a CRO in managing global infectious disease clinical trials, we are deeply committed to hemotune's pioneering strategy for combating septic shock. We recognize the potential for broader applications of their technology to selectively filter harmful agents from the bloodstream."